Dexmedetomidine-induced sedation in volunteers decreases regional and global cerebral blood flow.

  Pharmacokinetics of dexmedetomidine infusions for sedation of postoperative patients requiring intensive care.

  The efficacy, side effects, and recovery characteristics of dexmedetomidine versus propofol when used for intraoperative sedation.

  Effect of dexmedetomidine on propofol requirements in healthy subjects.

  Dual alpha(2)-adrenergic agonist and alpha(1)-adrenergic antagonist actions of dexmedetomidine on human isolated endothelium-denuded gastroepiploic arteries.

  The effects of increasing plasma concentrations of dexmedetomidine in humans.

  The pharmacokinetics of dexmedetomidine in volunteers with severe renal impairment.

  Assessment of the sedative effects of dexmedetomidine, an alpha 2-adrenoceptor agonist, with analysis of saccadic eye movements.

  Pharmacodynamics and pharmacokinetics of intramuscular dexmedetomidine.

  Dexmedetomidine decreases cerebral blood flow velocity in humans.

  Computer-controlled infusion of intravenous dexmedetomidine hydrochloride in adult human volunteers.

  The pharmacokinetics and hemodynamic effects of intravenous and intramuscular dexmedetomidine hydrochloride in adult human volunteers.

  Dexmedetomidine decreases thiopental dose requirement and alters distribution pharmacokinetics.

  Postoperative pharmacokinetics and sympatholytic effects of dexmedetomidine.

  Effects of dexmedetomidine on isoflurane requirements in healthy volunteers. 1: Pharmacodynamic and pharmacokinetic interactions.

    Back to Summaries List